Navigation Links
EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
Date:9/22/2008

AMSTERDAM, September 22 /PRNewswire/ -- Kiadis Pharma announced today that its lead product ATIR(TM) has been granted orphan drug designation (ODD) by the European Medicines Agency (EMEA) for the prevention of acute Graft versus Host Disease (GvHD) following an allogeneic bone marrow transplantation.

"Following the orphan drug designation granted by the FDA for our lead product ATIR(TM), this is another important milestone in the development of ATIR(TM) as a novel approach which may enable a safe and potentially life-saving mismatched bone marrow transplantation as a treatment option for end-stage blood cancer patients" says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.

The EMEA's orphan drug designation is reserved for new therapies being developed to treat life-threatening or chronically debilitating diseases or conditions that are relatively rare in the European Union and for which no satisfactory therapy is available. The orphan drug designation provides for incentives to support research and development, exemption from user fees and a ten-year period of market exclusivity in the European Union after product approval.

For the complete press release please go to: http://www.kiadis.com/news

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with three products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures performed in blood cancer patients. Kiadis Pharma is headquartered in Amsterdam, The Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit '/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  Custom Computer Specialists, Inc. ... that they are silver sponsors of the Primary Care ... sponsor, Custom is lending their support of PCDC,s mission ... Since its founding in 1993, PCDC has ... care area.  PCDC has financed over 100 completed primary ...
(Date:6/30/2015)... ... June 30, 2015 , ... Smarter Alloys today ... revolutionary new archwire that allows orthodontists to simultaneously apply different forces to different ... of SmartArch. “We’re thrilled about taking SmartArch one step closer to commercial availability ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... Under the terms of the agreement, MediVet will acquire the rights to a ... MB-007 is currently in pre-clinical development as a potential next-generation treatment for various ...
(Date:6/29/2015)... MARIETTA, Ga. , June 29, 2015  MiMedx ... medicine company utilizing human amniotic tissue and patent-protected processes ... the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic ... and CEO, Parker H. "Pete" Petit, has been awarded ... The Year® 2015 Southeast Program. The ...
Breaking Biology Technology:Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2
... Key Secondary Endpoints,NEW YORK, March 10 Intra-Cellular Therapies, ... Phase II trial in patients with Sleep Maintenance Insomnia ... increased slow wave sleep and decreased the duration of ... meeting the prespecified primary and key secondary endpoints of ...
... March 9 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... positive clinical study results for its Bio-Seal(TM) Lung ... Interventional Radiologists Annual Scientific Meeting in San Diego, ... of Bio-Seal in patients undergoing lung biopsy procedures ...
... 9 Former Presidential candidate Gary Bauer on Monday called ... embryonic stem cell research "evidence that ideology is the goal ... a tragedy, as lives will be lost and not saved ... Values made the following statement: "It,s tragic that Barack Obama ...
Cached Biology Technology:Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 3Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 4Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 5Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 6Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 7Angiotech announces positive results from Bio-Seal(TM) clinical study 2Angiotech announces positive results from Bio-Seal(TM) clinical study 3Angiotech announces positive results from Bio-Seal(TM) clinical study 4Angiotech announces positive results from Bio-Seal(TM) clinical study 5
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical ... use solutions, headquartered in Springville, Utah , ... California corporation with locations in Santa ... Rica ). This acquisition will incorporate MedConx,s ... ATL Technology,s existing facility in Costa Rica ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
(Date:6/23/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/vq2k2f/bodyworn ... "Body-Worn Temperature Sensors Market - Global Industry Analysis, ... 2020" report to their offering. ... body-worn temperature sensors market. The global body-worn temperature ... of types, care setting, patient demographic, applications and ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... A team from the National Institute of Standards ... Guard on a coordinated effort to train emergency first ... securing reliable samples of suspected biothreats. The project, dubbed ... first responders at the state, local and federal levels ...
... in the journal Annals of Botany , Professor Douglas ... in the ground could harvest more carbon from the air, ... levels. In principle, any crops could be treated in ... for the environment. Although the amount of carbon presently ...
... Nobel Prize for nerve growth factor was awarded more than ... use growth factor clinically. University of Pittsburgh Professor Yadong ... factor to regrow blood vessels. His research, which could be ... death in the Western world, is published this week in ...
Cached Biology News:Operation Vigilant Sample: First responder training for suspicious powders 2Crop breeding could 'slash CO2 levels' 2Regrowing blood vessels with a potent molecule 2Regrowing blood vessels with a potent molecule 3Regrowing blood vessels with a potent molecule 4
... performance spectral scanning multimode reader with ... advanced SkanIt Software it offers superior ... assay development. Varioskan provides unlimited wavelength ... and photometric assays and a dispenser ...
Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]...
... Effectively condenses and traps a wide variety of ... pump oil. Easy-to-use glass condensation flask (GCF400) allows ... contained jar for easy draining. Rapid cooling time ... glass flask for quick solvent changes ...
... Assays in Tris buffer, pH 10.2 give ... buffer system. Assays in diethanolamine buffer, pH ... the glycine buffer system. Protein determined by ... buffer salts Preparation Unit Definition: One unit ...
Biology Products: